NCT07020520 EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures
| NCT ID | NCT07020520 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Urotronic Inc. |
| Condition | Ureteral Stricture |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-10-01 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of this clinical investigation is to assess the safety and feasibility of the Optilume DCB for treatment of ureteric strictures.
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older 2. Single lesion ureteric or uretero-enteric stricture less than or equal to 4.0 cm in length 3. Two functioning kidneys Exclusion Criteria: 1. Treatment of the target ureter with incision or balloon dilation within 3 months of the study treatment 2. Subjects with more than one ureteric stricture 3. Subjects with target stricture in bifid or duplicated ureter 4. Known sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel 5. Ureteric stricture caused by extrinsic compression of the ureter 6. Unable to endoscopically access target stricture for any reason 7. Existing stones in the ipsilateral kidney or ureter (except for asymptomatic kidney stones) that are in close proximity to the target ureteric stricture 8. Chronic renal failure treated with dialysis 9. eGFR \<30 mL/min/1.73m2 10. Kidney function ≤ 25% of split function on the side with target stricture as measured by functional renogram 11. Kidney function ≤35% of split function on the side opposite target stricture as measured by functional renogram or other significant pathology or impairment that may impact renal function 12. Life expectancy less than 12 months 13. Women who are pregnant or breastfeeding 14. Women of child-bearing potential planning to get pregnant in the next year or are unwilling to use contraception over the next 12 months 15. Males unwilling to abstain or use protected sex for 30 days post treatment 16. Males unwilling to use highly effective contraception for6 months post treatment if sexual partner(s) are of child-bearing potential 17. Inability to provide legally effective informed consent 18. Unwilling or unable to meet protocol follow-up requirements 19. Participation in any interventional clinical investigation of a medical device, drug, or biologic (excluding registries) that may confound the results of the trial 20. Active systemic or urinary tract infection 21. Active malignancy in the abdomen or pelvis, or any malignancy considered considerable risk for metastasizing to the abdomen or pelvis over the next 12 months 22. Uncontrolled diabetes defined as hemoglobin A1C ≥ 8% at baseline 23. Unable to come off antiplatelet or anticoagulation medication prior to treatment to prevent bleeding complications at the discretion of the investigator 24. Any other condition that may confound the results of the trial or presents an unacceptable risk for any study-related procedure 25. Individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response 26. Presence of any condition that precludes administration of furosemide during renograms 27. Unable to tolerate contrast related to required study procedures or imaging. Additional Criteria for Pharmacokinetic Substudy Inclusion Ureteric stricture measurements appropriate for treatment with a 6mm (18F) or 8mm (24F) diameter Optilume DCB Exclusion Prior treatment with any device or medical therapy that contains paclitaxel, including drug coated balloons for vascular and urethral applications
Contact & Investigator
Jamie Landman, MD
PRINCIPAL INVESTIGATOR
University of California, Irvine
Frequently Asked Questions
Who can join the NCT07020520 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ureteral Stricture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07020520 currently recruiting?
Yes, NCT07020520 is actively recruiting participants. Contact the research team at smadej@laborie.com for enrollment information.
Where is the NCT07020520 trial being conducted?
This trial is being conducted at Orange, United States, Orlando, United States, Indianapolis, United States, New York, United States and 3 additional locations.
Who is sponsoring the NCT07020520 clinical trial?
NCT07020520 is sponsored by Urotronic Inc.. The principal investigator is Jamie Landman, MD at University of California, Irvine. The trial plans to enroll 60 participants.